Intensity Therapeutics (INTS) EPS (Basic) (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly EPS (Basic) came in at -$1.0 in Q1 2026, up 82.05% YoY from -$0.55 in Q1 2025, and up 55.63% on a QoQ basis from -$2.26 in Q4 2025.
Intensity Therapeutics (INTS) EPS (Basic) (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of EPS (Basic) data on file, last reported at -$1.0 in Q1 2026.
- Quarterly EPS (Basic) rose 82.05% year-over-year to -$1.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 (up 82.27% YoY) and the FY2025 annual result came in at -$8.74, up 70.1% from the prior year.
- EPS (Basic) climbed to -$1.0 in Q1 2026, from -$2.26 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$1.0 in Q1 2026 to a low of -$35.72 in Q2 2023.
- A 5-year average of -$8.8 and a median of -$7.38 in 2024 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2023 — EPS (Basic) sank 152.79% — and 2026, when it jumped 82.05%.
- Tracing INTS's EPS (Basic) over 5 years: stood at -$11.07 in 2022, then climbed by 16.89% to -$9.2 in 2023, then soared by 37.87% to -$5.72 in 2024, then surged by 60.42% to -$2.26 in 2025, then jumped by 55.63% to -$1.0 in 2026.
- The last three EPS (Basic) figures came in at -$1.0 (Q1 2026), -$2.26 (Q4 2025), and -$1.63 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | -1.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.15 |
| Mar 31, 2026 | -1.00 |
| Dec 31, 2025 | -2.26 |
| Sep 30, 2025 | -1.63 |
| Jun 30, 2025 | -3.61 |
| Mar 31, 2025 | -5.60 |
| Dec 31, 2024 | -5.72 |
| Sep 30, 2024 | -6.36 |
| Jun 30, 2024 | -9.06 |
| Mar 31, 2024 | -8.40 |
| Dec 31, 2023 | -9.20 |
| Sep 30, 2023 | -4.26 |
| Jun 30, 2023 | -35.72 |
| Mar 31, 2023 | -9.80 |
| Dec 31, 2022 | -11.07 |
| Sep 30, 2022 | -13.01 |
| Jun 30, 2022 | -14.13 |